Wolman's Disease Completed Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Wolman Disease / Disease, Wolman / Lipidoses NOS / Cerebrotendinous cholesterosis [van Bogaert-Scherer-Epstein]

IndicationStatusPhase
DBCOND0040271 (Wolman's Disease)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00383448HSCT for High Risk Inherited Inborn ErrorsTreatment